Emerging blood-brain barrier drugs in development
- By Martha Deja, Nicholas Buhay, Marc Herant, and Jason Brauner
- Biopharma
Despite the historical difficulty in designing therapeutics that cross the BBB, Denali’s landmark approval could signal an inflection point for the BBB-crossing therapeutic pipeline.